Jefferies, Citi, Guggenheim and Morgan Stanley started coverage of Zenas BioPharma (NASDAQ:ZBIO) with bullish ratings, citing the potential of its lead autoimmune drug candidate, obexelimab.

Morgan Stanley lowered the firm’s price target on Zenas BioPharma (ZBIO) to $35 from $40 and keeps an Overweight rating on the shares. The firm updated its model following Zenas’ recent ...

Zenas BioPharma, Inc.'s topline 12-week results, from the phase 2 MoonStone study using obexelimab for the treatment of patients with relapsing multiple sclerosis, are expected in Q3 of 2025.

Financially, Zenas reported a cash position of $314.2 million as of March 31, 2025, which is expected to support operations into the fourth quarter of 2026.

WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a ...

Zenas BioPharma has filed to raise $100 million in an IPO to advance its Phase 3 and Phase 2 trials for obexelimab. Click here to read an analysis of ZBIO stock.

Zenas BioPharma, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO Provided by PR Newswire Apr 28, 2025, 9:45:00 AM ...

Zenas BioPharma, which develops immunology-based therapies, said on Thursday that it has raised $225 million in its U.S. initial public offering (IPO).

Zenas BioPharma Inc. and Bicara Therapeutics Inc. on Friday both set estimated price ranges in their initial public offerings in a sign that the traditional summer lull in deals is coming to an end.

NEW YORK, June 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).

Zenas BioPharma, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights – ZBIO Provided by GlobeNewswire May 12, 2025 ...